Navigation Links
N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
Date:3/2/2011

BOULDER, Colo., March 2, 2011 /PRNewswire/ -- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. The data describe the preclinical safety evaluation of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR), and the lack of apparent mechanism-based toxicities. GSNOR is a critical enzyme in the endogenous nitric oxide pathway, and its activity is thought to be important in human respiratory, gastrointestinal and cardiovascular disease.  N30 Pharma's first GSNOR inhibitor, N6022, is currently in Phase 1b/2a testing. The poster will be available as a PDF on the N30 Pharma website after its presentation (www.n30pharma.com).

Event:  2011 Annual Meeting of the Society of Toxicology

Session Title and Date:  Pharmaceutical Safety Assessment:  Therapeutic Agents, March 7, 2011, 1 pm EST.

Poster:  Inhibition of the Enzyme S-nitrosoglutathione Reductase  (GSNOR) Does Not Cause Mechanism-Based Toxicity.  

Targeting GSNOR

GSNOR breaks down S-nitrosoglutathione (GSNO), reducing the body's pool of GSNO. In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects. Similarly, in the gut, GSNO supports barrier function and maintains the integrity of the gut surface. In asthmatics, GSNOR up-regulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy. GSNO has also been found to be important in the cardiovascular system as well as the control of breathing.

About inhibitors of GSNOR

N30 Pharma's portfolio of proprietary compounds provides a platform of potent, selective and reversible inhibitors of GSNOR. They increase levels of GSNO, an S-nitrosothiol that plays a central role in health and disease.


'/>"/>
SOURCE N30 Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
3. Access Pharmaceuticals to Host Update Conference Call for Investors
4. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
5. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
6. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
9. Endo Pharmaceuticals Raises 2011 Financial Guidance and Reports Strong Fourth Quarter 2010 Financial Results
10. MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology
11. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/10/2017)... June 9, 2017  Shane K. Burchfield, DPM, is recognized by ... as a Podiatrist in Alabama . ... First Foot Care. He brings over 20 years of experience, as ... and healthcare, to his role. ... PC is pleased to welcome you to his practice," ...
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... 26, 2017 , ... KICKICO , a protocol built on Ethereum for ... many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, which will ... the raising of funds through the power of many - has been around for ...
(Date:6/25/2017)... ... June 25, 2017 , ... An increase in wetter weather in ... plants, and along with that; a humdinger of an allergy season. A relief from ... an increase in misery-causing grass and weed pollen. , “Our patients have been ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s ... and Erie Convention Center on June 8-10. The weekend consisted of many ... award and scholarship presentations, and professional networking. , On Friday June 9th, ...
(Date:6/23/2017)... VA (PRWEB) , ... June 23, 2017 , ... ... of what is needed and will ultimately do significant harm to people with ... to everyone. , "While it leaves in place the Affordable Care Act ...
(Date:6/23/2017)... ... 2017 , ... Dr. Ran Y. Rubinstein , a ... offering three new minimally invasive procedures to patients who want a younger and ... Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich plasma (PRP) ...
Breaking Medicine News(10 mins):